Ischemia-Modified Albumin as a Possible Marker of Oxidative Stress in Patients with Telogen Effluvium

In 2020, two studies were conducted to investigate the role of ischemia-modified albumin (IMA) in telogen effluvium, a common hair loss condition. The first study involved 40 patients with telogen effluvium and 40 healthy controls, and found that IMA levels were significantly higher in patients, suggesting oxidative stress might play a role in the condition. The second study, involving 91 patients and 35 healthy volunteers, also found higher IMA values in patients, reinforcing the idea of oxidative stress's role in telogen effluvium. Both studies suggested that IMA could potentially be used as a marker for oxidative stress in patients with this condition.